Overall, our findings provide compelling evidence that ALDH3A2 overexpression inhibits GC progression by promoting ferroptosis through the ALDH3A2-SLC47A1-UPRmt-GPX4 axis, highlighting genistein as a potential therapeutic agent for GC therapy. The gene discussed is SLC47A1; the disease is gastric cancer.